Translate Bio and Sanofi to develop vaccines using mRNA tech

European approval for Opdivo/low dose Yervoy combo
Credit: Lemau Studio

Translate Bio has entered into a multi-year research and development collaboration and exclusive licensing agreement with Sanofi’s vaccine business to develop mRNA vaccines for up to five undisclosed infectious disease pathogens.

Under the agreement, Translate Bio and Sanofi Pasteur will jointly conduct research and development activities to advance mRNA vaccines during an initial three-year research term.

Sanofi Pasteur will make an upfront payment of $45 million to Translate Bio. In total, Translate Bio is eligible to receive up to $805 million in payments, which also includes certain development, regulatory and sales-related milestones.

In addition, Translate Bio is also eligible to receive tiered royalty payments associated with worldwide sales of the developed vaccines. Sanofi Pasteur will pay for all costs during the research term and will receive exclusive worldwide commercialization rights.

Translate Bio will be responsible for clinical manufacture and will be entitled to additional payments under a separate supply agreement to be established.

John Shiver, Senior Vice President, R&D, Sanofi Pasteur, said: “We believe mRNA technology has significant potential for rapid and versatile manufacturing, reduced industrialisation costs for multiple vaccines, and the improved breadth of immune response for infectious disease vaccines.

“The Translate Bio platform may allow us to further address medical needs worldwide, including those not readily accessible using conventional vaccine strategies.”